FDA’s On­col­o­gy Cen­ter of Ex­cel­lence touts 2018 ac­com­plish­ments

Im­age: Richard Paz­dur. FDA via FLICKR

The FDA’s re­cent­ly cre­at­ed in­ter-cen­ter On­col­o­gy Cen­ter of Ex­cel­lence (OCE) on Mon­day re­leased its first-ever an­nu­al re­port tout­ing its ac­com­plish­ments in 2018.

OCE was launched in 2017 to speed the de­vel­op­ment and re­view of on­col­o­gy prod­ucts across the FDA’s three med­ical prod­uct cen­ters.

“In 2018, we es­tab­lished a core OCE man­age­ment team and con­tin­ued the work be­gun in 2017 of build­ing pro­grams and launch­ing ini­tia­tives to lever­age ex­per­tise across the FDA and oth­er fed­er­al health agen­cies, as well as acad­e­mia, com­mu­ni­ty prac­ti­tion­ers, and in­dus­try, to ad­vance the de­vel­op­ment and reg­u­la­tion of prod­ucts for peo­ple with can­cer,” writes OCE Di­rec­tor Richard Paz­dur.

2018

With its goal of ex­pe­dit­ing the de­vel­op­ment and re­view of on­col­o­gy and hema­tol­ogy prod­ucts, OCE high­lights the num­ber of reg­u­la­to­ry de­ci­sions it made for new and ex­ist­ing prod­ucts in 2018.

These de­ci­sions in­clude the ap­proval of 19 new mol­e­c­u­lar en­ti­ties (NMEs) and orig­i­nal bi­o­log­ics li­cense ap­pli­ca­tions (BLAs), two biosim­i­lars and a pre­mar­ket ap­proval (PMA) for a new com­pan­ion di­ag­nos­tic that tests for a ge­net­ic mu­ta­tion in pa­tients with acute myeloid leukemia.

2018 On­col­o­gy Ap­provals
19 New Mol­e­c­u­lar En­ti­ties (NMEs)/Bi­o­log­ics Li­cense Ap­pli­ca­tions (BLAs) 32 Ef­fi­ca­cy Sup­ple­ments (New In­di­ca­tions) 1 Ef­fi­ca­cy Sup­ple­ment (New Pa­tient Pop­u­la­tion)
2 Ef­fi­ca­cy Sup­ple­ments (Ac­cel­er­at­ed Ap­proval Con­fir­ma­to­ry Study) 2 Biosim­i­lars 9 505(b)(2) Ap­provals
1 Pre­mar­ket Ap­proval (PMA) – (New Com­pan­ion Di­ag­nos­tic) 10 PMAs (Mod­i­fi­ca­tion to Com­pan­ion Di­ag­nos­tic) 1 PMA (Com­bi­na­tion Prod­uct

The re­port points out that 10 of these ap­provals lever­aged one or both of the cen­ter’s pi­lot re­view pro­grams, re­al time on­col­o­gy re­view (RTOR) and as­sess­ment aid (AAid).

The OCE al­so took part in re­view­ing more than 140 ap­pli­ca­tions for the FDA’s ex­pe­dit­ed pro­grams, in­clud­ing fast track, break­through ther­a­py des­ig­na­tion (BTD), re­gen­er­a­tive med­i­cine ad­vanced ther­a­py (RMAT) and break­through de­vice des­ig­na­tion.

OCE 2018 Ex­pe­dit­ed Pro­gram Sub­mis­sions
Ex­pe­dit­ed Pro­gram Grant­ed De­nied With­drawn
Fast Track 35 22 N/A
Break­through Ther­a­py 25 16 10
Re­gen­er­a­tive Med­i­cine Ad­vanced Ther­a­py 2 4 0
Break­through De­vice Des­ig­na­tion 18 5 4

In 2018, OCE helped de­vel­op 10 guid­ance and one fi­nal guid­ance doc­u­ments cov­er­ing a range of is­sues from clin­i­cal tri­al end­points for can­cer drugs to de­vel­op­ing and la­bel­ing com­pan­ion di­ag­nos­tics for spe­cif­ic on­col­o­gy ther­a­pies. OCE al­so con­vened 18 pub­lic work­shops and 16 ed­u­ca­tion­al sym­posia in 2018.

In­ter­na­tion­al Col­lab­o­ra­tion

Ke Liu

On the in­ter­na­tion­al front, Paz­dur along with OCE Act­ing As­so­ci­ate Di­rec­tor for Cell and Gene Ther­a­py Ke Liu and Act­ing As­sis­tant Com­mis­sion­er for In­ter­na­tion­al Pro­grams Leigh Ver­bois met with reg­u­la­tors, aca­d­e­mics and in­dus­try in Chi­na in Ju­ly 2018.

Leigh Ver­bois

“Dur­ing our vis­its to Bei­jing, Zhengzhou, Suzhou, and Shang­hai, we de­scribed FDA’s ini­tia­tives in ex­pe­dit­ing the de­vel­op­ment of on­col­o­gy prod­ucts, con­veyed the FDA’s ex­pe­ri­ence in ac­cel­er­at­ing the process of bring­ing in­no­v­a­tive ther­a­pies to mar­ket while main­tain­ing high stan­dards of safe­ty and ef­fi­ca­cy,” the re­port states.

OCE al­so holds month­ly on­col­o­gy in­ter­na­tion­al clus­ter meet­ings with its coun­ter­parts at the Eu­ro­pean Med­i­cines Agency, Health Cana­da, Japan’s Phar­ma­ceu­ti­cals and Med­ical De­vices Agency, Switzer­land’s Swissmedic and Aus­tralia’s Ther­a­peu­tic Goods Ad­min­is­tra­tion.


First pub­lished in Reg­u­la­to­ry Fo­cus™ by the Reg­u­la­to­ry Af­fairs Pro­fes­sion­als So­ci­ety, the largest glob­al or­ga­ni­za­tion of and for those in­volved with the reg­u­la­tion of health­care prod­ucts. Click here for more in­for­ma­tion.

John Hood [file photo]

UP­DATE: Cel­gene and the sci­en­tist who cham­pi­oned fe­dra­tinib's rise from Sanofi's R&D grave­yard win FDA OK

Six years after Sanofi gave it up for dead, the FDA has approved the myelofibrosis drug fedratinib, now owned by Celgene.

The drug will be sold as Inrebic, and will soon land in the portfolio at Bristol-Myers Squibb, which is finalizing a deal to acquire Celgene.

Endpoints News

Basic subscription required

Unlock this story instantly and join 57,400+ biopharma pros reading Endpoints daily — and it's free.

Ab­b­Vie gets its FDA OK for JAK in­hibitor upadac­i­tinib, but don’t look for this one to hit ex­ecs’ lofty ex­pec­ta­tions

Another big drug approval came through on Friday afternoon as the FDA OK’d AbbVie’s upadacitinib — an oral JAK1 inhibitor that is hitting the rheumatoid arthritis market with a black box warning of serious malignancies, infections and thrombosis reflecting fears associated with the class.

It will be sold as Rinvoq — at a wholesale price of $59,000 a year — and will likely soon face competition from a drug that AbbVie once controlled, and spurned. Reuters reports that a 4-week supply of Humira, by comparison, is $5,174, adding up to about $67,000 a year.

UP­DAT­ED: AveX­is sci­en­tif­ic founder was axed — and No­var­tis names a new CSO in wake of an ethics scan­dal

Now at the center of a storm of controversy over its decision to keep its knowledge of manipulated data hidden from regulators during an FDA review, Novartis CEO Vas Narasimhan has found a longtime veteran in the ranks to head the scientific work underway at AveXis, where the incident occurred. And the scientific founder has hit the exit.

Endpoints News

Basic subscription required

Unlock this story instantly and join 57,400+ biopharma pros reading Endpoints daily — and it's free.

The top 10 fran­chise drugs in bio­phar­ma his­to­ry will earn a to­tal of $1.4T (tril­lion) by 2024 — what does that tell us?

Just in case you were looking for more evidence of just how important Amgen’s patent win on Enbrel is for the company and its investors, EvaluatePharma has come up with a forward-looking consensus estimate on what the list of top 10 drugs will look like in 2024.

Endpoints News

Basic subscription required

Unlock this story instantly and join 57,400+ biopharma pros reading Endpoints daily — and it's free.

UP­DAT­ED: Sci­en­tist-CEO ac­cused of im­prop­er­ly us­ing con­fi­den­tial in­fo from uni­corn Alec­tor

The executive team at Alector $ALEC has a bone to pick with scientific co-founder Asa Abeliovich. Their latest quarterly rundown has this brief note buried inside:

On June 18, 2019, we initiated a confidential arbitration proceeding against Dr. Asa Abeliovich, our former consulting co-founder, related to alleged breaches of his consulting agreement and the improper use of our confidential information that he learned during the course of rendering services to us as our consulting Chief Scientific Officer/Chief Innovation Officer. We are in the early stage of this arbitration proceeding and are unable to assess or provide any assurances regarding its possible outcome.

There’s no explicit word in the filing on what kind of confidential info was involved, but the proceeding got started 2 days ahead of Abeliovich’s IPO.

Abeliovich, formerly a tenured associate professor at Columbia, is a top scientist in the field of neurodegeneration, which is where Alector is targeted. More recently, he’s also helped start up Prevail Therapeutics as the CEO, which raised $125 million in an IPO. And there he’s planning on working on new gene therapies that target genetically defined subpopulations of Parkinson’s disease. Followup programs target Gaucher disease, frontotemporal dementia and synucleinopathies.

But this time Abeliovich is the CEO rather than a founding scientist. And some of their pipeline overlaps with Alector’s.

Abeliovich and Prevail, though, aren’t taking this one lying down.

Endpoints News

Basic subscription required

Unlock this story instantly and join 57,400+ biopharma pros reading Endpoints daily — and it's free.

Chi­na has be­come a CEO-lev­el pri­or­i­ty for multi­na­tion­al phar­ma­ceu­ti­cal com­pa­nies: the trend and the im­pli­ca­tions

After a “hot” period of rapid growth between 2009 and 2012, and a relatively “cooler” period of slower growth from 2013 to 2015, China has once again become a top-of-mind priority for the CEOs of most large, multinational pharmaceutical companies.

At the International Pharma Forum, hosted in March in Beijing by the R&D Based Pharmaceutical Association Committee (RDPAC) and the Pharmaceutical Research and Manufacturers of America (PhRMA), no fewer than seven CEOs of major multinational pharmaceutical firms participated, including GSK, Eli Lilly, LEO Pharma, Merck KGaA, Pfizer, Sanofi and UCB. A few days earlier, the CEOs of several other large multinationals attended the China Development Forum, an annual business forum hosted by the research arm of China’s State Council. It’s hard to imagine any other country, except the US, having such drawing power at CEO level.

As dis­as­ter struck, Ab­b­Vie’s Rick Gon­za­lez swooped in on Al­ler­gan with an of­fer Brent Saun­ders couldn’t say no to

Early March was a no good, awful, terrible time for Allergan CEO Brent Saunders. His big lead drug had imploded in a Phase III disaster and activists were after his hide — or at least his chairman’s title — as the stock price continued a steady droop that had eviscerated share value for investors.

But it was a perfect time for AbbVie CEO Rick Gonzalez to pick up the phone and ask Saunders if he’d like to consider a “strategic” deal.

Endpoints News

Basic subscription required

Unlock this story instantly and join 57,400+ biopharma pros reading Endpoints daily — and it's free.

CEO Pascal Soriot via Getty Images

As­traZeneca's jug­ger­naut PARP play­er Lyn­parza scoops up an­oth­er dom­i­nant win in PhI­II as the FDA adds a 'break­through' for Calquence

AstraZeneca’s oncology R&D group under José Baselga keeps churning out hits.

Wednesday morning the pharma giant and their partners at Merck parted the curtains on a successful readout for their Phase III PAOLA-1 study, demonstrating statistically significant improvement in progression-free survival for women with ovarian cancer in a first-line maintenance setting who added their PARP Lynparza to Avastin. This is their second late-stage success in ovarian cancer, which will help stave off rivals like GSK.

Endpoints News

Basic subscription required

Unlock this story instantly and join 57,400+ biopharma pros reading Endpoints daily — and it's free.

ICER blasts FDA, PTC and Sarep­ta for high prices on DMD drugs Em­flaza, Ex­ondys 51

ICER has some strong words for PTC, Sarepta and the FDA as the US drug price watchdog concludes that as currently priced, their respective new treatments for Duchenne muscular dystrophy are decidedly not cost-effective.

The final report — which cements the conclusions of a draft issued in May — incorporates the opinion of a panel of 17 experts ICER convened in a public meeting last month. It also based its analysis of Emflaza (deflazacort) and Exondys 51 (eteplirsen) on updated annual costs of $81,400 and over $1 million, respectively, after citing “incorrect” lower numbers in the initial calculations.